Importantly, high ONECUT3 levels were associated with poor sensitivity to chemotherapy, suggesting that ONECUT3-targeted therapy may benefit the chemosensitization of MDS patients with CK. The gene discussed is ONECUT3; the disease is myelodysplastic syndrome.